Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Twist Bioscience Corporation TWST

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throu...


Recent & Breaking News (NDAQ:TWST)

Twist Bioscience Reports First Quarter 2022 Financial Results

Business Wire February 4, 2022

Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications

Business Wire February 1, 2022

Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability

Business Wire January 31, 2022

Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics

Business Wire January 25, 2022

Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022

Business Wire January 20, 2022

Twist Bioscience's Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference

Business Wire January 10, 2022

Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research

Business Wire January 6, 2022

Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants

Business Wire January 5, 2022

Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2022

Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing

Business Wire December 20, 2021

Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets

Business Wire December 16, 2021

Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests

Business Wire December 15, 2021

Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays

Business Wire December 7, 2021

Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors

Business Wire November 30, 2021

Twist Bioscience to Present at Upcoming Virtual Conferences

Business Wire November 24, 2021

Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results

Business Wire November 22, 2021

Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities

Business Wire November 22, 2021

Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs

Business Wire November 18, 2021

Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases

Business Wire November 15, 2021

Twist Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference

Business Wire November 9, 2021